You just read:

Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis

News provided by

Amira Pharmaceuticals, Inc.

Apr 19, 2011, 11:00 ET